Value20202021202220232024TTMSelling/general/admin expenses44.96 M34.91 M25.93 M31.94 M31.4 M28.68 MResearch & development101.61 M70.34 M75.54 M60.22 M89.34 M102.69 MOperating income158.84 M98.61 M96.63 M76.43 M116.59 M125.87 MNon-Operating Income, Total-8 000-3 00000——Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses-8 000-3 00000——Unusual income/expense——————Pretax income-159.57 M-98.19 M-96.2 M-72.72 M-113.86 M-125.01 MEquity in earnings——————Taxes-10 K-381 K70 K7 00055 K124 KNon-controlling/minority interest——————After tax other income/expense-655 K-656 K7 000-23 K3 000-342 KNet income before discontinued operations159.56 M97.81 M96.27 M72.73 M113.92 M125.13 MDiscontinued operations——————Net income159.56 M97.81 M96.27 M72.73 M113.92 M125.13 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders159.56 M97.81 M96.27 M72.73 M-113.92 M125.13 MBasic earnings per share (Basic EPS)——-12.4-7.6-1.17-1.04Diluted earnings per share (Diluted EPS)——-12.4-7.6-1.17-1.04Average basic shares outstanding——7.74 M9.51 M97 M442.88 MDiluted shares outstanding——7.74 M9.51 M97 M442.88 MEBITDA———-271.83 M——EBIT———-275.43 M——Cost of revenue———199 M——Other cost of goods sold——————Depreciation & amortization (cash flow)4.4 M4.4 M2.7 M3.6 M2.72 M—
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.